Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13,847 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Kroschinsky F, Middeke JM, Janz M, Lenz G, Witzens-Harig M, Bouabdallah R, La Rosée P, Viardot A, Salles G, Kim SJ, Kim TM, Ottmann O, Chromik J, Quinson AM, von Wangenheim U, Burkard U, Berk A, Schmitz N. Kroschinsky F, et al. Among authors: kim sj, kim tm. Invest New Drugs. 2020 Oct;38(5):1472-1482. doi: 10.1007/s10637-020-00916-3. Epub 2020 Mar 14. Invest New Drugs. 2020. PMID: 32172489 Free PMC article. Clinical Trial.
A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma.
Sym SJ, Lee DH, Kang HJ, Nam SH, Kim HY, Kim SJ, Eom HS, Kim WS, Suh C. Sym SJ, et al. Among authors: kim hy, kim sj, kim ws. Cancer Chemother Pharmacol. 2009 Jun;64(1):27-33. doi: 10.1007/s00280-008-0847-y. Epub 2008 Oct 7. Cancer Chemother Pharmacol. 2009. PMID: 18839172 Clinical Trial.
Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial.
Oh SY, Kim WS, Lee DH, Kim SJ, Kim SH, Ryoo BY, Kang HJ, Choi YJ, Chung JS, Kim HJ, Suh C. Oh SY, et al. Among authors: kim hj, kim sh, kim sj, kim ws. Invest New Drugs. 2010 Apr;28(2):171-7. doi: 10.1007/s10637-009-9260-6. Epub 2009 May 7. Invest New Drugs. 2010. PMID: 19421710 Clinical Trial.
Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity.
Kim SJ, Kim K, Park Y, Kim BS, Huh J, Ko YH, Park K, Suh C, Kim WS. Kim SJ, et al. Among authors: kim bs, kim ws, kim k. Invest New Drugs. 2012 Feb;30(1):368-75. doi: 10.1007/s10637-010-9523-2. Epub 2010 Aug 24. Invest New Drugs. 2012. PMID: 20734108 Clinical Trial.
Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group.
Kim SJ, Moon JH, Kim H, Kim JS, Hwang YY, Intragumtornchai T, Issaragrisil S, Kwak JY, Lee JJ, Won JH, Reksodiputro AH, Lim ST, Cheng AL, Kim WS, Kwong YL. Kim SJ, et al. Among authors: kim h, kim js, kim ws. Leuk Lymphoma. 2012 Aug;53(8):1515-24. doi: 10.3109/10428194.2012.659735. Epub 2012 Mar 1. Leuk Lymphoma. 2012. PMID: 22273250
Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
Kim SJ, Hsu C, Song YQ, Tay K, Hong XN, Cao J, Kim JS, Eom HS, Lee JH, Zhu J, Chang KM, Reksodiputro AH, Tan D, Goh YT, Lee J, Intragumtornchai T, Chng WJ, Cheng AL, Lim ST, Suh C, Kwong YL, Kim WS. Kim SJ, et al. Among authors: kim js, kim ws. Eur J Cancer. 2013 Nov;49(16):3486-96. doi: 10.1016/j.ejca.2013.07.006. Epub 2013 Aug 1. Eur J Cancer. 2013. PMID: 23910494
13,847 results
You have reached the last available page of results. Please see the User Guide for more information.